As of December 2021, several therapeutic treatments are available for mild-to-moderate COVID-19. These therapies are provided to states by the federal government and currently, supply of most of these therapies is extremely limited

Please note: Due to the presence of the Omicron variant and consistent with federal guidance, two monoclonal antibody (mAb) therapies, bamlanivimab/etesevimab and casirivimab/imdevimab, should no longer be used at this time.

Source link